We are developing a robust pipeline of novel therapeutic antibodies that mobilize the human immune system to combat cancer and autoimmune disorders. With a sharp focus on regulatory T cells and Myeloid-derived suppressor cells, our programs aim to modulate multiple immune cell types and key pathways. Highlights of our pipeline include:
We apply our proprietary single-cell functional antibody screening CelliGO™ platform and unique single-cell immune profiling Drug Intelligent Science (DIS™) capabilities to enable rapid identification of differentiated therapeutic molecules and significantly enhance clinical probability of success.
Key advantages of CelliGO include:
Key advantages of DIS include:
We continue to establish strategic partnerships with leading pharmaceutical and biotechnology companies, as well as academic institutions to help allocate resources more efficiently, expand single-cell analytics and accelerate commercialization. All of our collaborations are architected for speed and driven by our scientific strategy.
Our high scientific standards have been validated in numerous peer-reviewed publications and conference presentations.